Left breast irradiation with tangential intensity modulated radiotherapy (t-IMRT) versus tangential volumetric modulated arc therapy (t-VMAT): trade-offs between secondary cancer induction risk and optimal target coverage.
Adult
Aged
Carcinoma, Ductal, Breast
/ pathology
Carcinoma, Intraductal, Noninfiltrating
/ pathology
Female
Humans
Middle Aged
Neoplasm Invasiveness
Organs at Risk
/ radiation effects
Prognosis
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
/ methods
Radiotherapy, Intensity-Modulated
/ methods
Retrospective Studies
Unilateral Breast Neoplasms
/ pathology
Breast cancer
Cardiac dose
Deep inspiration breath hold
Homogeneity index (HI) and conformity index (CI)
Tangential intensity modulated radiotherapy (t-IMRT)
Tangential volumetric modulated arc therapy (t-VMAT). Normal tissue integral dose (NTID)
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
02 Sep 2019
02 Sep 2019
Historique:
received:
16
03
2019
accepted:
21
08
2019
entrez:
4
9
2019
pubmed:
4
9
2019
medline:
11
2
2020
Statut:
epublish
Résumé
Adjuvant radiotherapy is the standard treatment after breast-conserving surgery. According to meta-analyses, adjuvant 3d-conventional irradiation reduces the risk of local recurrence and thereby improves long-term survival by 5-10%. However, there is an unintended exposure of organs such as the heart, lungs and contralateral breast. Irradiation of the left breast has been related to long-term effects like increased rates of coronary events as well as second cancer induction. Modern radiotherapy techniques such as tangential intensity modulated radiotherapy (t-IMRT) and tangential volumetric modulated arc therapy (t-VMAT) and particularly deep inspiration breath hold (DIBH) technique have been developed in order to improve coverage of target volume and to reduce dose to normal tissue. The aim of this study was to compare t-IMRT-plans with t-VMAT-plans in DIBH position for left-sided breast irradiation in terms of normal tissue exposure, i.e. of lungs, heart, left anterior descending coronary artery (LADCA), as well as homogeneity (HI) and conformity index (CI) and excess absolute risk (EAR) for second cancer induction for organs at risk (OAR) after irradiation. Twenty patients, diagnosed with left-sided breast cancer and treated with breast-preserving surgery, were included in this planning study. For each patient DIBH-t-IMRT plan using 5 to 7 beams and t-VMAT plan using four rotations were generated to achieve 95% dose coverage to 95% of the volume. Data were evaluated on the basis of dose-volume histograms: Cardiac dose and LADCA (mean and maximum dose, D25% and D45%), dose to ipsilateral and contralateral lung (mean, D20%, D30%), dose to contralateral breast (mean dose), total monitor units, V5% of total body and normal tissue integral dose (NTID). In addition, homogeneity index and conformity index, as well as the excess absolute risk (EAR) to estimate the risk of second malignancy were calculated. T-IMRT showed a significant reduction in mean cardiac dose of 26% (p = 0.002) compared to t-VMAT, as well as a significant reduction in the mean dose to LADCA of 20% (p = 0.03). Following t-IMRT, mean dose to the left lung was increased by 5% (p = 0.006), whereas no significant difference was found in the mean dose to the right lung and contralateral breast between the two procedures. Monitor units were 31% (p = 0.000004) lower for t-IMRT than for t-VMAT. T-IMRT technique significantly reduced normal tissue integral dose (NTID) by 19% (p = 0.000005) and the V5% of total body by 24% (p = 0.0007). In contrast, t-VMAT improved CI and HI by 2% (p = 0.001) and 0.4% (p = 0.00001), respectively. EAR with t-IMRT was significantly lower, especially for contralateral lung and contralateral breast (2-5/10,000 person years) but not for ipsilateral lung. Compared to t-VMAT, t-IMRT in left-sided breast irradiation significantly reduced dose to organs at risk as well as normal tissue integral dose, and V5% total body. EAR with t-IMRT was significantly lower for contralateral lung and contralateral breast. T-VMAT, however, achieved better homogeneity and conformity. This may be relevant in individual cases where sufficient coverage of medial lymphatic target volumes is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Adjuvant radiotherapy is the standard treatment after breast-conserving surgery. According to meta-analyses, adjuvant 3d-conventional irradiation reduces the risk of local recurrence and thereby improves long-term survival by 5-10%. However, there is an unintended exposure of organs such as the heart, lungs and contralateral breast. Irradiation of the left breast has been related to long-term effects like increased rates of coronary events as well as second cancer induction. Modern radiotherapy techniques such as tangential intensity modulated radiotherapy (t-IMRT) and tangential volumetric modulated arc therapy (t-VMAT) and particularly deep inspiration breath hold (DIBH) technique have been developed in order to improve coverage of target volume and to reduce dose to normal tissue. The aim of this study was to compare t-IMRT-plans with t-VMAT-plans in DIBH position for left-sided breast irradiation in terms of normal tissue exposure, i.e. of lungs, heart, left anterior descending coronary artery (LADCA), as well as homogeneity (HI) and conformity index (CI) and excess absolute risk (EAR) for second cancer induction for organs at risk (OAR) after irradiation.
METHODS
METHODS
Twenty patients, diagnosed with left-sided breast cancer and treated with breast-preserving surgery, were included in this planning study. For each patient DIBH-t-IMRT plan using 5 to 7 beams and t-VMAT plan using four rotations were generated to achieve 95% dose coverage to 95% of the volume. Data were evaluated on the basis of dose-volume histograms: Cardiac dose and LADCA (mean and maximum dose, D25% and D45%), dose to ipsilateral and contralateral lung (mean, D20%, D30%), dose to contralateral breast (mean dose), total monitor units, V5% of total body and normal tissue integral dose (NTID). In addition, homogeneity index and conformity index, as well as the excess absolute risk (EAR) to estimate the risk of second malignancy were calculated.
RESULTS
RESULTS
T-IMRT showed a significant reduction in mean cardiac dose of 26% (p = 0.002) compared to t-VMAT, as well as a significant reduction in the mean dose to LADCA of 20% (p = 0.03). Following t-IMRT, mean dose to the left lung was increased by 5% (p = 0.006), whereas no significant difference was found in the mean dose to the right lung and contralateral breast between the two procedures. Monitor units were 31% (p = 0.000004) lower for t-IMRT than for t-VMAT. T-IMRT technique significantly reduced normal tissue integral dose (NTID) by 19% (p = 0.000005) and the V5% of total body by 24% (p = 0.0007). In contrast, t-VMAT improved CI and HI by 2% (p = 0.001) and 0.4% (p = 0.00001), respectively. EAR with t-IMRT was significantly lower, especially for contralateral lung and contralateral breast (2-5/10,000 person years) but not for ipsilateral lung.
CONCLUSION
CONCLUSIONS
Compared to t-VMAT, t-IMRT in left-sided breast irradiation significantly reduced dose to organs at risk as well as normal tissue integral dose, and V5% total body. EAR with t-IMRT was significantly lower for contralateral lung and contralateral breast. T-VMAT, however, achieved better homogeneity and conformity. This may be relevant in individual cases where sufficient coverage of medial lymphatic target volumes is warranted.
Identifiants
pubmed: 31477165
doi: 10.1186/s13014-019-1363-4
pii: 10.1186/s13014-019-1363-4
pmc: PMC6721379
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
156Références
Lancet. 1999 May 15;353(9165):1641-8
pubmed: 10335782
Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1559-68
pubmed: 11121662
Strahlenther Onkol. 2002 Jul;178(7):357-62
pubmed: 12163989
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1336-44
pubmed: 12459355
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1510-5
pubmed: 15817357
Lancet Oncol. 2005 Aug;6(8):557-65
pubmed: 16054566
Lancet. 2005 Dec 17;366(9503):2087-106
pubmed: 16360786
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
Radiat Environ Biophys. 2008 Apr;47(2):253-63
pubmed: 18157543
Med Phys. 2008 Jan;35(1):310-7
pubmed: 18293586
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1021-30
pubmed: 18556141
J Med Imaging Radiat Oncol. 2009 Feb;53(1):92-9
pubmed: 19453534
Med Phys. 2009 Apr;36(4):1138-43
pubmed: 19472619
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):287-95
pubmed: 19775832
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10-8
pubmed: 20421148
Radiother Oncol. 2010 Oct;97(1):65-70
pubmed: 20605245
Radiat Oncol. 2011 Mar 21;6:26
pubmed: 21418616
Radiat Oncol. 2011 Jun 08;6:67
pubmed: 21651799
Theor Biol Med Model. 2011 Jul 26;8:27
pubmed: 21791103
Cancer Radiother. 2011 Oct;15(6-7):495-503
pubmed: 21885320
Br J Radiol. 2011 Nov;84(1007):967-96
pubmed: 22011829
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Radiother Oncol. 2012 May;103(2):133-42
pubmed: 22391054
J Breast Cancer. 2012 Sep;15(3):337-43
pubmed: 23091547
J Med Phys. 2012 Oct;37(4):207-13
pubmed: 23293452
Acta Oncol. 2013 May;52(4):703-10
pubmed: 23421926
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
J Clin Oncol. 2013 Dec 20;31(36):4488-95
pubmed: 24043742
J Res Med Sci. 2013 May;18(5):413-6
pubmed: 24174948
Radiat Oncol J. 2013 Dec;31(4):191-8
pubmed: 24501706
Genes (Basel). 2011 Nov 29;2(4):1033-49
pubmed: 24710304
Asian Pac J Cancer Prev. 2014;15(11):4727-32
pubmed: 24969911
Asian Pac J Cancer Prev. 2014;15(20):9033-8
pubmed: 25374248
Asian Pac J Cancer Prev. 2015;16(4):1633-6
pubmed: 25743844
Radiat Oncol. 2015 Nov 17;10:231
pubmed: 26577189
Strahlenther Onkol. 2017 Oct;193(10):800-811
pubmed: 28646251
Strahlenther Onkol. 2018 Mar;194(3):196-205
pubmed: 28916844
Br J Radiol. 2017 Dec;90(1080):20170187
pubmed: 28937271
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):785-793
pubmed: 29249528
J Med Phys. 2017 Oct-Dec;42(4):234-240
pubmed: 29296037
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
Strahlenther Onkol. 2019 Jan;195(1):13-20
pubmed: 30143814
Radiat Oncol. 2018 Sep 24;13(1):187
pubmed: 30249274
PLoS One. 2018 Oct 19;13(10):e0205770
pubmed: 30339705
Strahlenther Onkol. 2019 Jan;195(1):32-42
pubmed: 30350118
Radiat Oncol. 2018 Nov 26;13(1):231
pubmed: 30477511
Radiat Oncol. 2018 Nov 28;13(1):236
pubmed: 30486829